SCHEMBL26349189

SCHEMBL26349189

[N-]=[N+]=NCCOCCOCCOCCN1C(=O)c2ccc3c4c(ccc(c24)C1=O)C(=O)N(CCOCCOCCOCCN=[N+]=[N-])C3=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGMT P16455 1/20 0.42
▸ TERT O14746 8/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ RGS12 O14924 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ PABPC1 P11940 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MGLL Q99685 1/20 0.39
▸ HEXA P06865 3/20 0.38
▸ HEXB P07686 3/20 0.38
▸ OGA O60502 1/20 0.38
▸ HPGD P15428 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29199650 0.88 HPGD (0.49) MGMTNPC1ALDH1A1RAB9AKMT2A
SCHEMBL14499669 0.87 HPGD (0.50) NPC1ALDH1A1RAB9AKMT2ASMN1; SMN2
SCHEMBL26349201 0.86 KDM4E (0.49) MGMTKDM4EMEN1ALDH1A1HTT
SCHEMBL30459062 0.84 CYP1B1 (0.53) KDM4EMEN1NPC1ALDH1A1LMNA
SCHEMBL15096386 0.84 CYP1B1 (0.53) KDM4EMEN1NPC1ALDH1A1LMNA
SCHEMBL30455266 0.84 CYP1B1 (0.53) KDM4EMEN1NPC1ALDH1A1LMNA
SCHEMBL26349215 0.82 ALDH1A1 (0.38) MGMTKDM4EALDH1A1HPGDNPSR1
SCHEMBL26349218 0.82 ALDH1A1 (0.52) MEN1NPC1ALDH1A1LMNARAB9A
SCHEMBL25495612 0.80 MGMT (0.42) MGMTMGLL
SCHEMBL26349212 0.79 MGMT (0.34) MGMTKDM4EMEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303502-A1 HETEROARYL AND HETEROCYCLYL COMPOUNDS SIGILON THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230303502-A1 HETEROARYL AND HETEROCYCLYL COMPOUNDS SIGILON THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230303502-A1 HETEROARYL AND HETEROCYCLYL COMPOUNDS SIGILON THERAPEUTICS, INC. 2023-09-28 — — US disclosed
EP-4192468-A2 HETEROARYL AND HETEROCYCLYL COMPOUNDS Sigilon Therapeutics, Inc. (US) 2023-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303502-A1 HETEROARYL AND HETEROCYCLYL COMPOUNDS CYP3A43, CYP2C9, CYP2C19 MGMT 2441/4885TERT 1215/4885KDM4E 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback